Detalles de la búsqueda
1.
Does the association between smoking and mortality differ due to frailty status? A secondary analysis from the Mexican Health and Aging Study.
Age Ageing
; 51(12)2022 12 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36477788
2.
Women with COPD from biomass smoke have reduced serum levels of biomarkers of angiogenesis and cancer, with EGFR predominating, compared to women with COPD from smoking.
Chron Respir Dis
; 18: 14799731211005023, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33787367
3.
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
J Infect Dis
; 220(3): 411-419, 2019 07 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31535143
4.
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
Gynecol Oncol
; 154(1): 110-117, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30982556
5.
miR-34a in serum is involved in mild-to-moderate COPD in women exposed to biomass smoke.
BMC Pulm Med
; 19(1): 227, 2019 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-31775690
6.
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Lancet
; 390(10108): 2143-2159, 2017 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28886907
7.
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
N Engl J Med
; 372(8): 711-23, 2015 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-25693011
8.
Women with COPD by biomass show different serum profile of adipokines, incretins, and peptide hormones than smokers.
Respir Res
; 19(1): 239, 2018 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30514305
9.
A 9-Valent HPV Vaccine in Women.
N Engl J Med
; 372(26): 2568-9, 2015 06 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-26107058
10.
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
Lancet Infect Dis
; 23(12): 1383-1394, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37660711
11.
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety.
Pediatrics
; 152(4)2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37667847
12.
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men.
Contemp Clin Trials
; 115: 106592, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34678491
13.
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.
Hum Vaccin Immunother
; 18(5): 2078626, 2022 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35853188
14.
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Lancet Infect Dis
; 22(3): 413-425, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34780705
15.
Air quality in Mexico City during the COVID-19 lockdown possibly decreased COPD exacerbations.
ERJ Open Res
; 8(4)2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36225332
16.
Clinical and microbiological characteristics and inflammatory profile during an exacerbation of COPD due to biomass exposure. A comparison with COPD due to tobacco exposure.
Respir Med
; 204: 107010, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36272858
17.
Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals.
Contemp Clin Trials
; 105: 106403, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33857679
18.
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up.
Hum Vaccin Immunother
; 17(4): 943-949, 2021 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33326342
19.
Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine.
Pediatrics
; 147(1)2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33386332
20.
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Lancet
; 373(9679): 1949-57, 2009 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-19493565